HLA-dependency and possible clinical relevance of intrathecally synthesized anti-IgLON5 IgG4 in anti-IgLON5 disease
Inga Koneczny, Stefan Macher, Hutterer Markus, Thomas Seifert-Held, Evelyn Seifert-Held, Morten Blaabjerg, Markus Breu, Jens Dreyhaupt, Livia Almeida Dutra, Markus Erdler, Ingrid Fae, Gottfried Fischer, Florian Frommlet, Anna Heidbreder, Birgit Högl, Veronika Klose, Sigrid Klotz, Herburg Liendl, Mette S. Nissen, Jasmin Rahimi, Raphael Reinecke, Gerda Ricken, Ambra Stefani, Marie Süße, Helio A.G. Teive, Serge Weis, Thomas Berger, Lidia Sabater, Carles Gaig, Jan Lewerenz, Romana Höftberger · FENS Forum 2024
Anti-IgLON5 disease is a rare autoimmune disorder with IgLON5 autoantibodies predominantly of the IgG4 subclass. The clinical relevance of the pathogenic effects of anti-IgLON5 IgG1 and IgG4 is unclear. IgLON5-specific IgG1-4 levels were measured in 46 sera and 20 cerebrospinal fluid (CSF) samples from 13 HLA-subtyped anti-IgLON5 disease patients (6 female, 7 male) using flow cytometry. Intervals between two consecutive serum or CSF samplings were analyzed for treatment, changes of anti-IgLON5 IgG1/IgG4 levels and disease severity. Intrathecal anti-IgLON5 IgG4 synthesis (IS) was assessed. Th
ePoster · Neuroscience